Sign In
Upcoming Event
Free Newsletter
An employee works with Proscia imaging technology - PHOTO/PROVIDED
HNL Lab Medicine investment to enhance diagnostic capabilities
Cris Collingwood//July 18, 2023//
HNL Lab Medicine is investing in an advanced digital pathology practice.
Allentown-based HNL Lab Medicine said has selected solutions from Proscia, a digital pathology software company, and Leica Biosystems, a manufacturer of high-quality imaging hardware, to establish the practice that will enhance the lab’s diagnostic capabilities, improve efficiency, and ultimately provide better patient care.
The initiative combines Proscia’s digital pathology software platform Concentriq Dx and Leica Biosystems’ scanner hardware.
Proscia’s Concentriq Dx drives routine workflows, streamlines collaboration and is designed for realizing the promise of pathology’s AI-powered future, HNL Lab Medicine said.
Combined with Leica Biosystems’ high throughput scanner hardware, the solution will enable HNL Lab Medicine’s pathologists to get to the correct diagnosis more efficiently, benefiting both patients and health care providers.
“We are excited to embark on this digital pathology journey with Proscia and Leica Biosystems,” said Dr. Jordan Olson, Medical Director of HNL Lab Medicine. “We chose Leica Biosystems as our whole slide imaging vendor due to their high image quality and demonstrated ability to handle large volumes. We selected Proscia’s Concentriq Dx as our digital pathology platform because it aligns with HNL Lab Medicine’s vision for innovation and efficiency.”
The two companies will allow HNL Lab Medicine to transform into a digital practice, enabling the company to deliver on the promise of precision medicine to improve patient care, Olson said.
“Each pathology image contains over one billion pixels that tell the story of a patient’s disease,” said David West, CEO of Proscia. “Beyond helping to drive quality and efficiency gains, HNL Lab Medicine lays the foundation for capitalizing on the full potential of this data with its digital pathology initiative.”
The substantial investment in digital pathology is part of HNL Lab Medicine’s ongoing commitment to harnessing advanced technologies to improve patient outcomes, Olson said.
